{"keywords":["BRAF","T cell","checkpoint","immunity","melanoma"],"genes":["Type I BRAF","host C-C chemokine receptor type 2","CCR2","BRAF"],"organisms":["10090"],"publicationTypes":["Journal Article"],"abstract":"Type I BRAF inhibitors and immunotherapy constitute two new exciting approaches for the treatment of advanced malignant melanoma. We have recently elucidated a role for host C-C chemokine receptor type 2 (CCR2) in the antineoplastic effects of type I BRAF inhibitors in mice, supporting the therapeutic potential of combining BRAF inhibitors with immunotherapy.","title":"BRAF-targeted therapy and immune responses to melanoma.","pubmedId":"23894707"}